Abiopharma

🔍 QUAIN MITCHELL I (Director)

Company: AstroNova, Inc. (ALOT)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Sold 108,910 shares of Common Stock at $29.0 per share (Direct)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,701 shares of Common Stock at $29.0 per share (Direct)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,000 shares of Stock Option (Right to Purchase) at $18.25 per share (Derivative)
  Date: 2026-08-26 | Code: D | Expires: 2028-06-04 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Sold 5,000 shares of Stock Option (Right to Purchase) at $13.9 per share (Derivative)
  Date: 2026-08-26 | Code: D | Expires: 2027-05-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated as of June 16, 2026, by and among AstroNova, Inc. (the "Company"), Orion Merger Parent, Inc. ("Parent"), and Orion MergerCo X, Inc., a wholly owned subsidiary of Parent (as it may be amended from time to time, the "Merger Agreement").
• F2: Shares held in a trust of which the reporting person is a trustee were disposed of pursuant to the Merger Agreement.
• F3: Stock Option originally granted on June 4, 2018, which became fully vested at the Company's 2019 Annual Meeting of Shareholders, and was cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $53,750, representing an amount equal to the product of: (i) the aggregate number of shares of the Company's common stock, par value $0.05 per share (the "Common Stock") subject to such Stock Option multiplied by (ii) the excess, if any, of $29.00 (the "Merger Consideration") over the per share exercise price under such Stock Option.
• F4: Stock Option originally granted on May 17, 2017, which became fully vested on May 17, 2018, and was cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $75,500, representing an amount equal to the product of: (i) the aggregate number of shares of the Company's common stock, par value $0.05 per share (the "Common Stock") subject to such Stock Option multiplied by (ii) the excess, if any, of $29.00 (the "Merger Consideration") over the per share exercise price under such Stock Option.